Code Stroke is a system for the rapid identification, pre-notification and transport of acute ischemic stroke patients. The objective of this study was to define quality indicators and to compare treatment outcomes in hospitals where Code Stroke has been implemented and hospitals without the use of Code Stroke (control patients).
In a first step qualitative technique has been conducted to define treatment quality indicators of acute ischemic stroke patients. In a second step a prospective study is conducted to collect data of 240 inpatients from two groups of hospitals. Two hospitals applying Code Stroke (N= 120) and four hospitals non-applying Code Stroke procedure (N=120). A consecutive sampling method will be conducted. Inclusion criteria: acute ischemic stroke patients treated in the hospitals during the field study. The referral to the hospital could be from primary care, Emergency Unit of other hospital. Patients will enroll after inform consent.
A Singer-blind- research method will applied. Quality indicators defined in the first phase will be applied and comparisons will be realized using ANOVA.
- Code Stroke Procedure
Intervention Desc: Apply a protocol called Code Stroke that involves the entire care chain from emergency teams outpatient specialists of Neurology, Internal Medicine, Radiology or Intensitivos Care, among other hospital areas. ARM 1: Kind: Experimental Label: Group A Description: Hospital using Code Stroke
- Allocation: Non-Randomized
- Masking: Single Blind (Investigator)
- Purpose: Health Services Research
- Endpoint: Safety/Efficacy Study
- Intervention: Parallel Assignment
- Observation: Case Control
- Perspective: Prospective
|Type||Measure||Time Frame||Safety Issue|
|Primary||Recovery rate of the Intravenous trombolysis treatment||1 month||Yes|
|Secondary||Patient satisfaction||1 month||No|
|Secondary||Patient engage||1 month||No|
|Secondary||response capacity||1 day||No|
|Secondary||Treatment adequacy: Intravenous trombolysis treatment||1 month||Yes|
|Secondary||Patient safety. Complications in the recombinant tissue plasminogen activator treatment after tromobysis||1 month||Yes|
|Secondary||Mortality rates of the Intravenous trombolysis treatment||1 month||Yes|